Neuropathic pain syndrome is a challenge to treat and, even with appropriate evidence-based treatment, only a 40% reduction of symptoms can be achieved in approximately half of patients.

Although evidence exists suggesting that some diseases causing neuropathic pain respond differently to the same medications, [85] we can conclude that it seems inevitable to base a treatment ...

Nalu Medical, Inc. ("Nalu"), a leader in peripheral nerve stimulation, announced the publication of a study in Pain ...

Finnerup NB, Kuner R, Jensen TS: Neuropathic pain: from mechanisms to treatment. Physiol Rev 2021; 101: 259–301 CrossRef MEDLINE 9. Gangadharan V, Zheng H, Taberner FJ, et al.: Neuropathic pain ...

Pacira BioSciences PCRX announced that the FDA has cleared its application to market a new Smart Tip for the iovera system ...

A Manitoba woman is suing St. Boniface Hospital and two staff after undergoing a medical procedure that she says left her ...

Nerve pain is distinct from typical tissue pain ... to determine the underlying cause of your pain and the best treatment option for you.

Pacira launches a new iovera° Smart Tip for chronic back pain relief, offering an alternative to radiofrequency ablation with ...

A single-center retrospective study in China found a significant association between pain duration and intensity in patients ...

Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, announced today that it has received clearance ...

Treatment with XG005 resulted in statistically significant and clinically meaningful reduction in post-surgical pain ...

For people suffering from chronic knee pain, especially those over 50, a new treatment is offering hope and relief.